Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms.
about
A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorderUpdate of sleep alterations in depressionThe noradrenergic symptom cluster: clinical expression and neuropharmacology.Depression in Parkinson's disease: symptom improvement and residual symptoms after acute pharmacologic management.Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medicationExtended release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: pooled analyses of data in patients with anxious depression versus low levels of anxiety at baseline.Major depressive disorder: mechanism-based prescribing for personalized medicineVulnerability to somatic symptoms of depression during interferon-alpha therapy for hepatitis C: a 16-week prospective study.Adipocytokine signaling is altered in Flinders sensitive line rats, and adiponectin correlates in humans with some symptoms of depression.Qualitative Research on Fatigue Associated with Depression: Content Validity of the Fatigue Associated with Depression Questionnaire (FAsD-V2).The Fatigue Associated with Depression Questionnaire (FAsD): responsiveness and responder definition.Does duloxetine improve cognitive function independently of its antidepressant effect in patients with major depressive disorder and subjective reports of cognitive dysfunction?The antidepressant agomelatine improves the quality of life of depressed patients: implications for remission.Reconsidering GHB: orphan drug or new model antidepressant?Extended-release quetiapine fumarate in the treatment of patients with major depressive disorder: adjunct therapy.Factors associated with failure to achieve remission and with relapse after remission in patients with major depressive disorder in the PERFORM study.Resolution of sleepiness and fatigue: a comparison of bupropion and selective serotonin reuptake inhibitors in subjects with major depressive disorder achieving remission at doses approved in the European Union.Astroglial correlates of neuropsychiatric disease: From astrocytopathy to astrogliosis.Early non-response in patients with severe depression: escitalopram up-titration versus switch to duloxetine.The cut-off points of the Depression and Somatic Symptoms Scale and the Hospital Anxiety and Depression Scale in detecting non-full remission and a current major depressive episode.
P2860
Q24564427-F758F1FA-78D1-46CA-B2E4-942FD4125601Q26781426-A3A5E58F-6C8F-416B-88F6-20628509CB12Q30474844-B038DB30-2659-4824-A81A-61F1F46BE380Q34442089-15CAC0A8-FCFB-4207-91B0-1EBEA8786FF1Q34627169-019F9109-5FEF-45CC-8641-E0EB17B6F55DQ35088837-9BDFDAF9-9344-4C79-8E40-AC6F9D8315C4Q35284412-EA7F0538-7755-4F7A-B644-5A803D340F61Q35535322-67B5531F-E117-460F-A9CE-64E41D5F54DDQ35535351-5AB511A9-3A23-4834-9A7A-9DFDFB7072BCQ36073604-F97723FC-F56F-4DBE-8E3D-5B150C34F27FQ36622049-9C75F29B-CE84-471F-BE5F-7AC482FC1829Q37561682-E2E725BA-6D22-4BB6-801D-80CC838397A0Q37776074-4B8A8047-DAB5-4522-AF2C-274CDAAB992EQ37934335-73778CA2-27DD-488D-95E3-F0391981675EQ38157027-993FF9EE-B5B5-47F4-8FC5-101A8336DD6BQ40062026-B78E2EDD-4188-4792-80B3-D1DECC5796DAQ43567081-A885070C-181E-43CB-A23A-631572721B9AQ47680320-AE088AF3-82FF-4D3E-A8CF-33B532B485E7Q48686121-D51502DD-413A-47E2-99AD-9190F35ED8E8Q48797679-A2AE2B6E-D356-4D86-802D-32E2D7EDE52A
P2860
Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Strategies to enhance the ther ...... : targeting residual symptoms.
@en
Strategies to enhance the ther ...... : targeting residual symptoms.
@nl
type
label
Strategies to enhance the ther ...... : targeting residual symptoms.
@en
Strategies to enhance the ther ...... : targeting residual symptoms.
@nl
prefLabel
Strategies to enhance the ther ...... : targeting residual symptoms.
@en
Strategies to enhance the ther ...... : targeting residual symptoms.
@nl
P2093
P2860
P356
P1476
Strategies to enhance the ther ...... : targeting residual symptoms.
@en
P2093
Benji T Kurian
Madhukar H Trivedi
Tracy L Greer
P2860
P304
P356
10.1586/ERN.09.53
P577
2009-07-01T00:00:00Z